The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), ...

Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab)as an add-on maintenance treatment for adult patients with inadequately ...

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...

Mepolizumab added to triple therapy improves exacerbation outcomes in moderate to severe COPD and is effective to 2 years of ...

UK pharma major GSK (LSE: GSK) yesterday announced that the US Food and Drug Administration (FDA) has approved Nucala ...